1. Karyopharm will participate in the 2025 RBC Capital Markets Conference. 2. Senior management's discussion is set for May 21 in New York. 3. Karyopharm focuses on novel cancer therapies, highlighting XPOVIO's approvals. 4. Pipeline targets multiple cancers with unmet needs, such as myeloma and DLBCL. 5. Live webcast available, increasing investor engagement opportunities.
The participation in key conferences can lead to increased visibility and investor interest, similar to how previous conferences positively impacted other pharmaceutical stocks like Moderna during discussions on vaccine advancements.
KPTI's active management involvement in public events often correlates with stock activity, warranting attention during earnings seasons or product updates.
The conference's immediate impact on investor perception and potential stock movement will likely be shortly after the event, similar to events held by biotech peers demonstrating novel products or research advancements.
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York, NY.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
SOURCE Karyopharm Therapeutics Inc.